Regeneron Pharmaceuticals (NASDAQ: REGN)
Regeneron Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Regeneron Pharmaceuticals Company Info
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
News & Analysis
Should You Buy the Dip on This Top Growth Stock?
The biotech needs to overcome an issue most drugmakers face at some point.
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
These stocks have generally delivered competitive returns.
Is Regeneron Pharmaceuticals Due for a Stock Split?
Would a stock split help lead Regeneron Pharmaceuticals shares higher?
Should You Sell This Stock Following a Regulatory Roadblock?
It's not the first such obstacle this high-performing drugmaker has faced.
2 Biotech Stocks to Buy Hand Over Fist in March
These stocks are worth buying in most months of the year.
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
These businesses are on paths to extremely bright futures.
Could Regeneron Stock Help You Retire a Millionaire?
The blossoming biotech might give more than a nudge to investors in this project.
2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)
These innovative biotechs likely aren't done rewarding their shareholders.
Valuation
Podcast Episodes
Regeneron Stock Up on COVID-19 Breakthrough
Regeneron Pharmaceuticals stock got a shot in the arm after it announced a possible drug candidate for coronavirus.
Biotech Stocks Made Big Progress Toward Preventing Heart Attacks in 2018
Key trials suggest doctors may change how they treat patients with cardiovascular disease.
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.